KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) ranks twelfth on the list of 20 Best Biotech Stocks Under $20 to Buy Now. TD Cowen analyst raised the price target on KALV to $35 from $30 with a Buy rating ahead of its Q4 results. H.C. Wainwright analyst also raised the price target to $37 from $27 with a Buy rating, citing confidence in the company’s fiscal 2025 revenue. KalVista focuses on developing small-molecule protease inhibitors for rare diseases like hereditary angioedema. While KALV shows potential, some AI stocks offer greater upside and less downside risk.

Read more at Yahoo Finance: TD Cowen Bullish on KalVista Pharmaceuticals, Inc. (KALV) Ahead of Q4 Results